CEO David Pidduck has Stated Desire to Cash Out at Current Levels Pidduck and Current Board Do Not Have Conviction in MediPharm or its Long-Term Value Creation Strategy Apollo Capital has a Plan to Increase MediPharm Share Price from $0.07 to Over $1.00 in Th…

The costs incurred in the preparation and mailing of any circular or proxy solicitation by Apollo Capital and any other participants named herein will be borne directly and indirectly by Apollo Capit…